#Germany #Frankfurt #gene therapy #Cell Therapy #Cellex

Cellex Symposium 2025: Advancing Cell and Gene Therapy

On November 6, 2025, the Cellex Cell Professionals GmbH hosted a significant international symposium in Frankfurt Main titled "The Evolving Field of Cell and Gene Therapy." The event attracted over 100 participants from Europe, Asia, and North America, engaging leading experts from academia, industry, clinical practices, investors, and regulatory bodies to discuss current advancements and future directions in the rapidly developing field of cell and gene therapy (CGT).

Dr. Armin Ehninger, head of Science and Strategy at Cellex Cell Professionals, highlighted the company's commitment to advancing CGT. He emphasized the critical role of scientific excellence, collaborative exchange, reliable manufacturing, and the highest quality standards in driving innovations and building networks that enable significant advancements in modern therapies.

Driving Innovation and Investments in Immuno-cellular Therapies

The opening session focused on innovation, financing, and next-generation platforms for immuno-cell therapies. Dr. Karl Nägler from Sofinnova Partners provided an insightful overview of the opportunities and challenges in venture capital investments in CGT. Kenneth Locke discussed the utilization of cell-derived nanoparticles to overcome significant barriers in the activation and proliferation of T-cells. Additionally, Dr. Jiri Eitler from the Technical University of Dresden presented novel access strategies for CAR-NK therapies in oncology and beyond. Dr. Jessica Hartmann from the Paul-Ehrlich-Institut underscored the need for sustainable innovation, which relies on solid frameworks that can translate scientific breakthroughs into scalable, high-quality manufacturing solutions—an area where Cellex continuously sets new industry standards.

Clinical Navigation: Transforming Innovations into Patient Care

The session titled "Clinical Navigation" illuminated new therapeutic possibilities and the digital transformation in the clinical landscape. Professors Dimitrios Mougiakakos from the University Hospital Magdeburg and Ralf Gold from Ruhr University Bochum presented groundbreaking work on CAR-T therapies for autoimmune and neuromuscular diseases. Moreover, Professor Christof Scheid from the University Hospital of Cologne shared initial experiences on how outpatient CAR-T therapy models are becoming clinical realities. Dr. Moritz Middeke of Cancilico showcased how AI can be integrated into cancer diagnostics and treatment, explaining how AI-assisted decisions can accelerate precision medicine.

In a panel discussion titled "Cell and Gene Therapy 2035: Transformative Changes in Science, Systems, and Scope," industry leaders and scientists exchanged ideas with the audience to explore ways to broaden access to CGT therapies, future manufacturing transformations, the role of AI in treatment decisions, and anticipated disruptive innovations over the next decade.

Manufacturing and Quality: Strategic Accelerators of Innovation

The last session shifted focus to manufacturing. Gabriela Valentová from Johnson & Johnson opened with insights on how early and meaningful data can optimize manufacturing outcomes. Tom Brenner from the Stefan-Morsch Foundation addressed challenges in sourcing donor material and integrating registries. Dr. Gunther Busam from Orchard Therapeutics discussed process design for scalability and supply efficiency, while Professor Michael Hudecek from the University Hospital of Würzburg and Dr. Marcus Dühren-von Minden of SinABiomedics showcased innovations in CAR-T manufacturing and the development of the first tumor-specific CAR-T for CLL. These discussions emphasized a central message: CMC capabilities are not merely operational necessities but strategic prerequisites. Cellex’s integrated approach to process development, production analytics, and quality management demonstrates how strong manufacturing infrastructures can support both scientific progress and clinical implementation in CGT.

Networking, Diversity, and Dynamic Collaboration

Aside from the scientific agenda, the Cellex Symposium 2025 provided a platform for interdisciplinary exchange and collaboration. Researchers, clinicians, and industry representatives discussed ways to enhance therapy accessibility, harmonize standards, and integrate data-driven quality control into CGT manufacturing.

Professor Gerhard Ehninger, founder and CEO of Cellex Cell Professionals, remarked, "The success of the Cellex Symposium 2025 underscores our belief that progress in CGT requires both scientific excellence and the collaboration of many brilliant minds." He continued, "Cellex is proud to contribute to these global efforts by connecting different strata of expertise across the field."

About Cellex Cell Professionals GmbH

Cellex Cell Professionals is a leading CDMO specializing in CGT, offering comprehensive services. With state-of-the-art facilities in Cologne and a proven track record of over a decade in GMP-compliant manufacture of autologous and allogeneic cell therapies, Cellex collaborates with numerous large pharmaceutical and innovative biotech companies to support process development as well as clinical and commercial manufacturing. Additionally, Cellex provides customized materials from healthy donors and patients affected by specific diseases for research, clinical, and commercial purposes, along with storage and logistics services. For further information, visit www.cellex.me/en.